SEARCH

SEARCH BY CITATION

References

  • 1
    Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130: 64350.
  • 2
    De Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 12716.
  • 3
    Graf LL, Welsh CH, Qamar Z, Marlar RA. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden. Am J Clin Pathol 2003; 119: 5260.
  • 4
    Curvers J, Thomassen MC, Rimmer J, Hamulyak K, Van Der MJ, Tans G, Preston FE, Rosing J. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost 2002; 88: 511.
  • 5
    Tans G, Van HV, Thomassen MC, Curvers J, Bertina RM, Rosing J, Rosendaal FR. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003; 122: 46570.
  • 6
    Ehrenforth S, Radtke KP, Scharrer I. Acquired activated protein C-resistance in patients with lupus anticoagulants. Thromb Haemost 1995; 74: 7978.
  • 7
    Viveros ME, Cabiedes J, Reyes E, Cabral AR. Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies. Rev Invest Clin 2005; 57: 56371.
  • 8
    Galli M, Willems GM, Rosing J, Janssen RM, Govers-Riemslag JW, Comfurius P, Barbui T, Zwaal RF, Bevers EM. Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C. Br J Haematol 2005; 129: 2407.
  • 9
    Gardiner C, Cohen H, Jenkins A, Machin SJ, Mackie IJ. Detection of acquired resistance to activated protein C associated with antiphospholipid antibodies using a novel clotting assay. Blood Coagul Fibrinolysis 2006; 17: 47783.
  • 10
    Safa O, Esmon CT, Esmon NL. Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-beta(2)-glycoprotein I monoclonal antibodies. Blood 2005; 106: 162935.
  • 11
    Wahl D, Regnault V, Beguin S, De Maistre E, Kaminsky P, Hemker HC, Lecompte T. Thrombography allows reliable study of the protein C system in APS and evidences a strong phenotypic heterogeneity. Thromb Res 2004; 114: 63940.
  • 12
    Regnault V, Beguin S, Wahl D, De Maistre E, Coenraad HH, Lecompte T. Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants. Thromb Haemost 2003; 89: 20812.
  • 13
    Galli M, Ruggeri L, Barbui T. Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood 1998; 91: 19992004.
  • 14
    Male C, Mitchell L, Julian J, Vegh P, Joshua P, Adams M, David M, Andrew ME. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2001; 97: 8449.
  • 15
    Nojima J, Kuratsune H, Suehisa E, Iwatani Y, Kanakura Y. Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism. Clin Chem 2005; 51: 54552.
  • 16
    Regnault V, Hemker HC, Wahl D, Lecompte T. Phenotyping the haemostatic system by thrombography–potential for the estimation of thrombotic risk. Thromb Res 2004; 114: 53945.
  • 17
    Liestøl S, Sandset PM, Jacobsen EM, Mowinckel M-C, Wisloff F. Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants. Br J Haematol 2007; 136: 1317.
  • 18
    Hemker HC, Giesen P, Al Dieri R, Regnault V, De Smedt E, Wagenvoord R, Lecompte T, Beguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 415.
  • 19
    Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 130911.
  • 20
    Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost 1995; 74: 1597603.
  • 21
    Schjetlein R, Sletnes KE, Wisloff F. A quantitative, semi-automated and computer-assisted test for lupus anticoagulant. Thromb Res 1993; 69: 23950.
  • 22
    Svensson PJ, Zoller B, Dahlback B. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 1997; 77: 3325.
  • 23
    Altman DG. Statistical Tables. Practical Statistics for Medical Research. London: Chapman and Hall, 1991: 51445.
  • 24
    Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995; 95: 30916.
  • 25
    Esmon NL, Smirnov MD, Esmon CT. Lupus anticoagulants and thrombosis: the role of phospholipids. Haematologica 1997; 82: 4747.
  • 26
    Sheng Y, Hanly JG, Reddel SW, Kouts S, Guerin J, Koike T, Ichikawa K, Sturgess A, Krilis SA. Detection of ‘antiphospholipid’ antibodies: a single chromogenic assay of thrombin generation sensitively detects lupus anticoagulants, anticardiolipin antibodies, plus antibodies binding beta(2)-glycoprotein I and prothrombin. Clin Exp Immunol 2001; 124: 5028.
  • 27
    Carson CW, Comp PC, Rezaie AR, Esmon NL, Esmon CT. Antibodies to thrombomodulin are found in patients with lupus anticoagulant and unexplained thrombosis. J Rheumatol 2000; 27: 38490.